Wegovy Tracker App
Navigate the 16-week titration ladder to 2.4 mg semaglutide. Track weekly auto-injector pen shots, model active 7-day half-life curves, and benchmark your progress against the STEP 1 trial on iOS.
GLPme is a specialized Wegovy tracker designed for the 16-week titration ladder to 2.4 mg and long-term set-point defense. Track your single-dose pen injections, visualize 7-day semaglutide half-life curves, monitor cardiovascular health trends aligned with the landmark SELECT trial, and prevent tissue scarring through guided site rotation. 100% private and subscription-free on iOS.
Key takeaways
- Navigates the mandatory 5-step Wegovy titration ladder: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg.
- Benchmarked against STEP 1 (14.9% trial weight loss) and SELECT (20% cardiovascular event reduction).
- 7-day elimination half-life curve predicts Day 5/6 hunger troughs before they catch you off guard.
- Interactive injection quadrant map guides safe rotation across stomach and thighs.
- Completely private on iPhone: no cloud database, no mandatory accounts, no ads.
The 5-step Wegovy titration schedule
Wegovy follows a strict 16-week titration sequence to reach the licensed 2.4 mg maintenance dose:
- Month 1 (0.25 mg): Gastrointestinal conditioning.
- Month 2 (0.5 mg): Early satiety signals and mild appetite suppression.
- Month 3 (1.0 mg): Established weight loss velocity.
- Month 4 (1.7 mg): Pre-maintenance consolidation (or optional long-term maintenance).
- Month 5+ (2.4 mg): Full therapeutic maintenance dose evaluated in the STEP and SELECT clinical trials.
GLPme prevents injection schedule confusion by tracking your exact calendar dates, alerting you when each 4-week box is finishing, and reminding you when to contact your prescriber for the next dose strength.
Tracking cardiovascular and metabolic progress
In November 2023, the New England Journal of Medicine published the landmark SELECT trial results: 2.4 mg semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal stroke, and non-fatal heart attack) by 20% in non-diabetic adults with overweight or obesity. GLPme tracks resting heart rate, blood pressure, and activity alongside your weekly shot dates, providing an integrated view of cardiometabolic health.
Single-dose auto-injector pen safety rules
Wegovy pens in the United States feature a hidden needle auto-injector mechanism that fires upon firm skin contact. GLPme includes pre-shot checklist reminders: allowing the pen to warm for 20 minutes to prevent injection stinging, rotating between abdominal quadrants and upper thighs, and holding the pen firmly against skin for a full 10 seconds until the yellow indicator bar stops moving.
Long-term 2.4 mg maintenance & set-point defense
In the STEP 4 trial, patients who stopped Wegovy after 20 weeks regained 6.9% of their body weight, while those continuing on 2.4 mg lost an additional 7.9%. GLPme is built for the long haul: once you hit goal weight, the app transitions into Maintenance Mode, tracking weight stability, protein intake, and set-point defense.
Sources
Every figure on this page traces to one of these. Regulatory documents and peer-reviewed primary research only — see our editorial policy for what we accept as a source.
- WEGOVY (semaglutide) injection, US prescribing information. FDA, 2025. View source
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. View source
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021. View source
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023. View source
- GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic. View source
Download GLPme for Wegovy Free
Track your 16-week titration ladder and visualize your active semaglutide curve on iPhone.
